Posterior cingulate cortex microRNA dysregulation differentiates cognitive resilience, mild cognitive impairment, and Alzheimer's disease

IF 13 1区医学 Q1 CLINICAL NEUROLOGY

Alzheimer's & Dementia Pub Date : 2025-02-26 DOI:10.1002/alz.70019

Scott E. Counts, John S. Beck, Bryan Maloney, Michael Malek-Ahmadi, Stephen D. Ginsberg, Elliott J. Mufson, Debomoy K. Lahiri

{"title":"Posterior cingulate cortex microRNA dysregulation differentiates cognitive resilience, mild cognitive impairment, and Alzheimer's disease","authors":"Scott E. Counts, John S. Beck, Bryan Maloney, Michael Malek-Ahmadi, Stephen D. Ginsberg, Elliott J. Mufson, Debomoy K. Lahiri","doi":"10.1002/alz.70019","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>MicroRNA (miRNA) activity is increasingly appreciated as a key regulator of pathophysiologic pathways in Alzheimer's disease (AD). However, the role of miRNAs during the progression of AD, including resilience and prodromal syndromes such as mild cognitive impairment (MCI), remains underexplored.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>We performed miRNA-sequencing on samples of posterior cingulate cortex (PCC) obtained <i>post mortem</i> from Rush Religious Orders Study participants diagnosed <i>ante mortem</i> with no cognitive impairment (NCI), MCI, or AD. NCI subjects were subdivided as low pathology (Braak stage I/II) or high pathology (Braak stage III/IV), suggestive of resilience. Bioinformatics approaches included differential expression, messenger RNA (mRNA) target prediction, interactome modeling, functional enrichment, and AD risk modeling.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>We identified specific miRNA groups, mRNA targets, and signaling pathways distinguishing AD, MCI, resilience, <i>ante mortem</i> neuropsychological test performance, <i>post mortem</i> neuropathological burden, and AD risk.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>These findings highlight the potential of harnessing miRNA activity to manipulate disease-modifying pathways in AD, with implications for precision medicine.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>MicroRNA (MiRNA) dysregulation is a well-established feature of Alzheimer's disease (AD).</li>\n \n <li>Novel miRNAs also distinguish subjects with mild cognitive impairment and putative resilience.</li>\n \n <li>MiRNAs correlate with cognitive performance and neuropathological burden.</li>\n \n <li>Select miRNAs are associated with AD risk with age as a significant covariate.</li>\n \n <li>MiRNA pathways include insulin, prolactin, kinases, and neurite plasticity.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 2","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70019","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.70019","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

INTRODUCTION

MicroRNA (miRNA) activity is increasingly appreciated as a key regulator of pathophysiologic pathways in Alzheimer's disease (AD). However, the role of miRNAs during the progression of AD, including resilience and prodromal syndromes such as mild cognitive impairment (MCI), remains underexplored.

METHODS

We performed miRNA-sequencing on samples of posterior cingulate cortex (PCC) obtained post mortem from Rush Religious Orders Study participants diagnosed ante mortem with no cognitive impairment (NCI), MCI, or AD. NCI subjects were subdivided as low pathology (Braak stage I/II) or high pathology (Braak stage III/IV), suggestive of resilience. Bioinformatics approaches included differential expression, messenger RNA (mRNA) target prediction, interactome modeling, functional enrichment, and AD risk modeling.

RESULTS

We identified specific miRNA groups, mRNA targets, and signaling pathways distinguishing AD, MCI, resilience, ante mortem neuropsychological test performance, post mortem neuropathological burden, and AD risk.

DISCUSSION

These findings highlight the potential of harnessing miRNA activity to manipulate disease-modifying pathways in AD, with implications for precision medicine.

Highlights

MicroRNA (MiRNA) dysregulation is a well-established feature of Alzheimer's disease (AD).
Novel miRNAs also distinguish subjects with mild cognitive impairment and putative resilience.
MiRNAs correlate with cognitive performance and neuropathological burden.
Select miRNAs are associated with AD risk with age as a significant covariate.
MiRNA pathways include insulin, prolactin, kinases, and neurite plasticity.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer's & Dementia 医学-临床神经学

CiteScore

14.50

自引率

5.00%

发文量

299

审稿时长

3 months

期刊介绍： Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.